Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
CAMBRIDGE, Mass., Feb. 28, 2017 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the company is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston on Monday, March 6, 2017 at 2:00 p.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Contacts Investors: Kendra Adams, 617-844-6407 Senior Director, Investor & Public Relations [email protected] Renee Leck, 617-649-8299 Senior Manager, Investor & Public Relations [email protected]
